# Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel

Source: https://onco.cc/trials/nct07765446/  
OnCo record `nct07765446` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SIR2501 in advanced solid tumours, run by Sironax USA, Inc., now recruiting.

## Summary

Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel is a phase 2 interventional study registered as NCT07765446 by Sironax USA, Inc., with 18 participants planned, started 2026-08-21 and due to reach its primary completion in 2027-12-31. Interventions recorded: SIR2501.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07765446
- Phase: 2
- Setting: A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy
- Sponsor: Sironax USA, Inc.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT07765446: https://clinicaltrials.gov/study/NCT07765446

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07765446.json